Results 151 to 160 of about 5,633 (190)

Assessing willingness to pay for HLA-B*58:01 genetic testing before allopurinol initiation and its potential impact on future health policy, Thailand. [PDF]

Sci Rep
Towiwat P, Bamrungsawad N, Buttham B, Nakham A, Upakdee N.   +4 more
europepmc   +1 more source

Preinfusion Glucocorticoid Reduction and Elimination in Patients With Uncontrolled Gout on Pegloticase and Methotrexate: A Case Series. [PDF]

J Clin Rheumatol
Albert J, Vranic Z, LaMoreaux B, LaMoreaux B.   +3 more
europepmc   +1 more source

Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report. [PDF]

Front Immunol
Tan J, Huang H, Tan L, Li B, She R, Long S.   +5 more
europepmc   +1 more source

Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. [PDF]

Front Endocrinol (Lausanne)
Li X, Chen Z, Zhang Y, Fan C, Chen L, Xu X, Chang J, Qiang W, Jiang H, Liu C.   +9 more
europepmc   +1 more source

Bioequivalence evaluation of generic febuxostat versus Feburic^® in healthy Chinese subjects: a randomized crossover study. [PDF]

BMC Pharmacol Toxicol
Wang F, Ye X, Li F, Kong H, Liao M, Kan M, Zhuang J, Wang A, Meng X.   +8 more
europepmc   +1 more source

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study. [PDF]

Clin Rheumatol
Magagnoli J, Cummings TH, Ambati M, Sutton SS, Ambati J.   +4 more
europepmc   +1 more source

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study. [PDF]

Front Endocrinol (Lausanne)
Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Douguchi S, Ofuchi K, Katoh M.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Febuxostat

Reactions Weekly, 2016
Mit Febuxostat steht eine Alternative zu Allopurinol zur Verfügung. Seine Wirkung auf die Harnsäurespiegel ist gut dokumentiert; ob das Mittel in Bezug auf die praktisch relevanten Gichtsymptome ebenbürtig ist oder besser abschneidet, ist bisher nicht klar.
  +6 more sources

Febuxostat

Drugs, 2008
*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout. *In a randomized, double-blind, dose-ranging study in patients with gout and hyperuricaemia, significantly more recipients of febuxostat 40-120 mg/day than placebo had serum urate levels
Philip I, Hair, Paul L, McCormack, Gillian M, Keating   +2 more
openaire   +4 more sources

▼Febuxostat for gout

Drug and Therapeutics Bulletin, 2010
Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years.1–3 Acute gout is intensely painful and can reduce patients’ quality of life.2,3 It occurs when the serum uric acid concentration (SUA) rises (hyperuricaemia) and persists above the solubility threshold of ...
openaire   +2 more sources